Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery
Open Access
- 2 December 2022
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 136 (23), 1731-1758
- https://doi.org/10.1042/cs20210862
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide. An ongoing challenge remains the development of novel pharmacotherapies to treat CVD, particularly atherosclerosis. Effective mechanism-informed development and translation of new drugs requires a deep understanding of the known and currently unknown biological mechanisms underpinning atherosclerosis, accompanied by optimization of traditional drug discovery approaches. Current animal models do not precisely recapitulate the pathobiology underpinning human CVD. Accordingly, a fundamental limitation in early-stage drug discovery has been the lack of consensus regarding an appropriate experimental in vivo model that can mimic human atherosclerosis. However, when coupled with a clear understanding of the specific advantages and limitations of the model employed, preclinical animal models remain a crucial component for evaluating pharmacological interventions. Within this perspective, we will provide an overview of the mechanisms and modalities of atherosclerotic drugs, including those in the preclinical and early clinical development stage. Additionally, we highlight recent preclinical models that have improved our understanding of atherosclerosis and associated clinical consequences and propose model adaptations to facilitate the development of new and effective treatments.Keywords
This publication has 212 references indexed in Scilit:
- A Novel Rat Model of Type 2 Diabetes: The Zucker Fatty Diabetes Mellitus ZFDM RatJournal of Diabetes Research, 2013
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman PrimatesMolecular Therapy, 2012
- Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasomeCell Death & Disease, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progressionProceedings of the National Academy of Sciences of the United States of America, 2006
- Loss of Siglec expression on T lymphocytes during human evolutionProceedings of the National Academy of Sciences of the United States of America, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences of the United States of America, 2004
- The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophagesNature, 2003